SBRT plus immunotherapy and targeted therapy for kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your kidney cancer must be confirmed and have come back or spread to other parts of the body.
- You can have up to 5 metastatic tumors, or more than 5 tumors as long as at least 3 of them can be treated with radiation.
- Your age is between 18 and 80 years old.
- You are expected to live for at least 12 weeks.
- Your tumors can be measured on scans (RECIST criteria).
- Your daily activity level is fairly good (ECOG score 0-2, meaning you can take care of yourself and are up and about at least half the day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial tests whether adding a cholesterol-lowering drug (atorvastatin) to the standard combination of two cancer drugs (axitinib and toripalimab) can improve outcomes for people with advanced clear cell kidney cancer that cannot be removed by surgery or has spread. The goal is to see if this three-drug approach is safe and effective.
This trial tests a combination of precise radiation (SBRT) plus two drugs (anlotinib and bimepolizumab) to see if it helps control advanced kidney cancer. The goal is to shrink tumors and slow the cancer's growth.
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
Hear when a new Radiation Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.